Literature DB >> 30824813

The NKG2A immune checkpoint - a new direction in cancer immunotherapy.

Benjamin C Creelan1, Scott J Antonia2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30824813     DOI： 10.1038/s41571-019-0182-8

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  25 in total

Review 1.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

2.  The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.

Authors:  Quaovi H Sodji; Dhanya K Nambiar; Vignesh Viswanathan; Rie von Eyben; Deana Colburg; Michael S Binkley; Caiyun G Li; Monica M Olcina; Daniel T Chang; Quynh-Thu Le; Amato J Giaccia
Journal:  Cancer Res Commun       Date:  2022-07-27

3.  Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3.

Authors:  Stephanie Grebinoski; Qianxia Zhang; Anthony R Cillo; Sasikanth Manne; Hanxi Xiao; Erin A Brunazzi; Tracy Tabib; Carly Cardello; Christine G Lian; George F Murphy; Robert Lafyatis; E John Wherry; Jishnu Das; Creg J Workman; Dario A A Vignali
Journal:  Nat Immunol       Date:  2022-05-26       Impact factor: 31.250

Review 4.  Sweet Immune Checkpoint Targets to Enhance T Cell Therapy.

Authors:  Nohelly Derosiers; William Aguilar; David A DeGaramo; Avery D Posey
Journal:  J Immunol       Date:  2022-01-15       Impact factor: 5.426

Review 5.  Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?

Authors:  Robert W Lentz; Meryl D Colton; Siddhartha S Mitra; Wells A Messersmith
Journal:  Mol Cancer Ther       Date:  2021-04-13       Impact factor: 6.009

Review 6.  CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.

Authors:  Ezgi Elmas; Noushin Saljoughian; Marcelo de Souza Fernandes Pereira; Brian P Tullius; Kinnari Sorathia; Robin J Nakkula; Dean A Lee; Meisam Naeimi Kararoudi
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738

Review 7.  Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.

Authors:  Rohit Shetty; Arkasubhra Ghosh; Santosh G Honavar; Pooja Khamar; Swaminathan Sethu
Journal:  Indian J Ophthalmol       Date:  2020-05       Impact factor: 1.848

Review 8.  Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.

Authors:  Cai Zhang; Yuxia Liu
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

Review 9.  A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.

Authors:  Yunzhao R Ren; Amit Golding; Alfred Sorbello; Ping Ji; Jianmeng Chen; Bhawana Saluja; Kimberly Witzmann; Vikram Arya; Kellie S Reynolds; Su-Young Choi; Nikolay P Nikolov; Chandrahas Sahajwalla
Journal:  J Clin Pharmacol       Date:  2020-06-24       Impact factor: 2.860

10.  Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates.

Authors:  M D Fahlberg; R V Blair; L A Doyle-Meyers; C C Midkiff; G Zenere; K E Russell-Lodrigue; C J Monjure; E H Haupt; T P Penney; G Lehmicke; B M Threeton; N Golden; P K Datta; C J Roy; R P Bohm; N J Maness; T Fischer; J Rappaport; M Vaccari
Journal:  Nat Commun       Date:  2020-11-27       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.